Automated Pathology Slide Analysis

AI models analyze digitized whole-slide images (WSIs) to quantify tumor characteristics—such as mitotic count, nuclear pleomorphism, and tubule formation—in seconds. This provides objective, reproducible grading (e.g., Gleason score for prostate cancer, Nottingham score for breast cancer) that reduces inter-pathologist variability.

• Real Example: A major cancer center reduced prostate biopsy grading time from 15 to 2 minutes per case, increasing lab throughput by 40%.
• ROI Impact: Faster staging enables earlier treatment decisions, improving patient outcomes and increasing hospital capacity for complex cases.

Manually scoring immunohistochemistry (IHC) slides for biomarkers like HER2, PD-L1, and Ki-67 is time-consuming and subjective. AI provides precise, pixel-level quantification of staining intensity and distribution.

• Real Example: A pharmaceutical CRO automated PD-L1 scoring for clinical trials, cutting analysis time per patient by 70% and ensuring consistent, audit-ready results across global sites.
• ROI Impact: Enables high-volume, standardized biomarker analysis essential for personalized therapy selection and clinical trial endpoints, reducing operational costs and accelerating drug development.

Human fatigue leads to missed diagnoses, especially in high-volume screening environments like cervical Pap smears or breast cancer margins. AI acts as a safety-net, pre-screening tool, flagging suspicious regions for pathologist review.

• Real Example: A national lab network deployed AI for breast cancer margin assessment, catching 15% more micrometastases in sentinel lymph node biopsies that were initially missed, reducing false negatives.
• ROI Impact: Minimizes costly diagnostic errors, malpractice risk, and patient harm. Reduces the need for expensive secondary reviews and repeat procedures.

Pathologists spend up to 40% of their time on routine, low-complexity screenings. AI triages and prioritizes slides, routing urgent and complex cases first and providing preliminary annotations.

• Real Example: A regional hospital lab implemented a slide triage system, allowing pathologists to focus on high-value diagnostic work. This reduced average case turnaround time from 48 to 24 hours.
• ROI Impact: Maximizes the utilization of scarce, expensive specialist talent. Increases lab capacity without adding headcount, directly improving patient satisfaction and competitive service offerings.

AI is the engine that makes digital pathology archives valuable. It enables automated search and retrieval of similar historical cases for comparison and supports telepathology for expert consults.

• Real Example: A multi-hospital system uses AI to instantly retrieve morphologically similar cases from a archive of 2 million slides, providing diagnostic support for rare cancers and improving junior pathologist training.
• ROI Impact: Breaks down geographical barriers to expertise, reduces costs associated with physical slide transport, and creates a scalable knowledge base that appreciates in value over time.

Beyond known biomarkers, AI can identify novel morphometric features in tissue architecture that correlate with patient outcomes or treatment response—patterns invisible to the human eye.

• Real Example: Research institutions use AI to discover new stromal and immune cell spatial arrangements in colorectal cancer that predict recurrence risk more accurately than standard staging.
• ROI Impact: Creates proprietary intellectual property for hospitals and biopharma. Enables development of next-generation companion diagnostics and more precise patient stratification for clinical trials.